Octahydroindolo-[2,3-a]quinolizin-l-yl-alkanecarboxylic acid amides and salts thereof
申请人:RICHTER GEDEON VEGYESZETI GYAR R.T.
公开号:EP0177361A2
公开(公告)日:1986-04-09
The invention relates to new 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-1-yl-alkanecarboxylic acid amides of the general formula (I),
wherein
R, and R2 represent a hydrogen or halogen atom, or a hydroxyl, nitro or C1-4 alkoxy group;
R3 and R4 represent a hydrogen atom or a C1-4 alkyl group;
R5 and R6 represent a hydrogen atom, C1-8 alkyl group, C3-8 alkenyl or cycloalkyl group, aryl or aralkyl group, heteroaryl or heteroaralkyl goup containing oxygen, nitrogen or sulphur atom, all these goups being optionally substituted; or
R5 and R6 together represent a,w-alkyl group, wherein one carbon atom may optionally be replaced by an oxygen or nitrogen atom; and
G means a C1-4 straight chained alkylidene group, as well as to their therapeutically useful acid addition salts and pharmaceutical compositions containing these compounds.
Furthermore, the invention relates to a process for preparing these compounds and compositions.
The compounds of the general formula (I) have valuable therapeutic properties, namely vasodilatory, spasmolytic, antiarrhythmic and gastrocytoprotective effects. The gastrocytoprotective effect is particularly important.
本发明涉及通式 (I) 的新 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-1-yl-alkanecarboxylic acid amides、
其中
R 和 R2 代表氢原子或卤素原子,或羟基、硝基或 C1-4 烷氧基;
R3 和 R4 代表氢原子或 C1-4 烷基;
R5 和 R6 代表氢原子、C1-8 烷基、C3-8 烯基或环烷基、芳基或芳烷基、含有氧原子、氮原子或硫原子的杂芳基或杂烷基,所有这些基团均可选择被取代;或
R5 和 R6 共同代表一个 w-烷基,其中一个碳原子可任选被氧原子或氮原子取代;以及
G 指 C1-4 直链亚烷基,以及它们在治疗上有用的酸加成盐和含有这些化合物的药物组合物。
此外,本发明还涉及制备这些化合物和组合物的工艺。
通式(I)化合物具有宝贵的治疗特性,即血管扩张、解痉、抗心律失常和胃囊保护作用。其中胃囊保护作用尤为重要。